What was the primary cancer for keytruda's first fda approval?

What cancer did Keytruda’s first FDA approval target?

Keytruda (pembrolizumab) received its first FDA approval for melanoma—specifically unresectable or metastatic melanoma in patients who had progressed after ipilimumab and, if applicable, a BRAF inhibitor for those with the BRAF V600 mutation. [1]

When was Keytruda first approved and how did the indication read?

That initial FDA approval was in 2014, and the indication was aimed at late-stage melanoma patients whose disease had worsened after prior therapies. [1]

Source

1. DrugPatentWatch.com (Keytruda/pembrolizumab FDA approval history): https://www.drugpatentwatch.com/